Does Rallies show 13F holders for TYRA?

Yes. Rallies tracks hedge fund and 13F ownership data for TYRA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TYRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TYRA. It does not provide personalized investment advice.

TYRA (Tyra Biosciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Tyra Biosciences, Inc. Common Stock (TYRA) is a publicly traded Healthcare sector company. As of May 21, 2026, TYRA trades at $33.16 with a market cap of $2.12B and a P/E ratio of -16.75. TYRA moved -1.04% today. Year to date, TYRA is +27.04%; over the trailing twelve months it is +234.67%. Its 52-week range spans $6.42 to $40.65. Analyst consensus is strong buy with an average price target of $50.30. Rallies surfaces TYRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TYRA stock?

Hedge funds tracked by Rallies that own TYRA include Farallon Capital and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tyra Biosciences, Inc. Common Stock.

TYRA Key Metrics

Key financial metrics for TYRA
Metric	Value
Price	$33.16
Market Cap	$2.12B
P/E Ratio	-16.75
EPS	$-2.01
Dividend Yield	0.00%
52-Week High	$40.65
52-Week Low	$6.42
Volume	40
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-119.95M
Gross Margin	0.00%

Top Hedge Funds Holding TYRA

Farallon Capital holds 3.58M shares of TYRA, changed +73.25% as of Mar 31, 2026.
Orbimed Advisors holds 804.60K shares of TYRA, changed -54.10% as of Jun 30, 2025.

Latest TYRA News

Tyra Biosciences Holds $383.5M Cash, Doses First Patient in SURF303 — May 13, 2026
Tyra Biosciences Appoints Habib Dable to Board to Advance Dabogratinib Commercialization — Apr 17, 2026
Tyra Biosciences Raises $256M Cash, Eyes SURF302 and BEACH301 Data in 2026 — Mar 2, 2026
Tyra Biosciences Sees >70% NMIBC CR Rate by Mid-Year, Advances UTUC Trial — Mar 2, 2026

Recent TYRA Insider Trades

KAPLAN GILLA sold 14.29K (~$528.51K) on Mar 25, 2026.
Bensen Daniel sold 2.13K (~$67.04K) on Feb 12, 2026.
Bensen Daniel sold 5.87K (~$195.93K) on Feb 12, 2026.

TYRA Analyst Consensus

13 analysts cover TYRA: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.30.

Common questions about TYRA

Who owns TYRA stock?: Hedge funds tracked by Rallies that own TYRA include Farallon Capital and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Tyra Biosciences, Inc. Common Stock.
Does Rallies show 13F holders for TYRA?: Yes. Rallies tracks hedge fund and 13F ownership data for TYRA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TYRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TYRA. It does not provide personalized investment advice.